FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893960509> ?p ?o ?g. }

• W2893960509 endingPage "2229" @default.
• W2893960509 startingPage "2220" @default.
• W2893960509 abstract "Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)-programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy.We conducted this double-blind, placebo-controlled, phase 3 trial to evaluate atezolizumab plus carboplatin and etoposide in patients with extensive-stage small-cell lung cancer who had not previously received treatment. Patients were randomly assigned in a 1:1 ratio to receive carboplatin and etoposide with either atezolizumab or placebo for four 21-day cycles (induction phase), followed by a maintenance phase during which they received either atezolizumab or placebo (according to the previous random assignment) until they had unacceptable toxic effects, disease progression according to Response Evaluation Criteria in Solid Tumors, version 1.1, or no additional clinical benefit. The two primary end points were investigator-assessed progression-free survival and overall survival in the intention-to-treat population.A total of 201 patients were randomly assigned to the atezolizumab group, and 202 patients to the placebo group. At a median follow-up of 13.9 months, the median overall survival was 12.3 months in the atezolizumab group and 10.3 months in the placebo group (hazard ratio for death, 0.70; 95% confidence interval [CI], 0.54 to 0.91; P=0.007). The median progression-free survival was 5.2 months and 4.3 months, respectively (hazard ratio for disease progression or death, 0.77; 95% CI, 0.62 to 0.96; P=0.02). The safety profile of atezolizumab plus carboplatin and etoposide was consistent with the previously reported safety profile of the individual agents, with no new findings observed.The addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by F. Hoffmann-La Roche/Genentech; IMpower133 ClinicalTrials.gov number, NCT02763579 .)." @default.
• W2893960509 created "2018-10-05" @default.
• W2893960509 creator A5006496749 @default.
• W2893960509 creator A5007665505 @default.
• W2893960509 creator A5012226414 @default.
• W2893960509 creator A5019770739 @default.
• W2893960509 creator A5036764789 @default.
• W2893960509 creator A5043871151 @default.
• W2893960509 creator A5047703113 @default.
• W2893960509 creator A5049192558 @default.
• W2893960509 creator A5049294543 @default.
• W2893960509 creator A5054842148 @default.
• W2893960509 creator A5060572768 @default.
• W2893960509 creator A5062894702 @default.
• W2893960509 creator A5066717752 @default.
• W2893960509 creator A5071440718 @default.
• W2893960509 creator A5072962574 @default.
• W2893960509 creator A5073572288 @default.
• W2893960509 creator A5074173103 @default.
• W2893960509 creator A5078287634 @default.
• W2893960509 creator A5078389632 @default.
• W2893960509 creator A5080125836 @default.
• W2893960509 creator A5083662358 @default.
• W2893960509 date "2018-12-06" @default.
• W2893960509 modified "2023-10-18" @default.
• W2893960509 title "First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer" @default.
• W2893960509 cites W1916687048 @default.
• W2893960509 cites W2023171799 @default.
• W2893960509 cites W2058264985 @default.
• W2893960509 cites W2060499368 @default.
• W2893960509 cites W2074552727 @default.
• W2893960509 cites W2094723762 @default.
• W2893960509 cites W2108927999 @default.
• W2893960509 cites W2124427232 @default.
• W2893960509 cites W2155723257 @default.
• W2893960509 cites W2156202615 @default.
• W2893960509 cites W2293531514 @default.
• W2893960509 cites W2330814896 @default.
• W2893960509 cites W2418354692 @default.
• W2893960509 cites W2480201404 @default.
• W2893960509 cites W2567564314 @default.
• W2893960509 cites W2588150967 @default.
• W2893960509 cites W2737084095 @default.
• W2893960509 cites W2745840031 @default.
• W2893960509 cites W2783897381 @default.
• W2893960509 cites W2787666307 @default.
• W2893960509 cites W2797855256 @default.
• W2893960509 cites W2800160190 @default.
• W2893960509 cites W2804287047 @default.
• W2893960509 cites W2806596191 @default.
• W2893960509 cites W2886963239 @default.
• W2893960509 doi "https://doi.org/10.1056/nejmoa1809064" @default.
• W2893960509 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30280641" @default.
• W2893960509 hasPublicationYear "2018" @default.
• W2893960509 type Work @default.
• W2893960509 sameAs 2893960509 @default.
• W2893960509 citedByCount "1966" @default.
• W2893960509 countsByYear W28939605092017 @default.
• W2893960509 countsByYear W28939605092018 @default.
• W2893960509 countsByYear W28939605092019 @default.
• W2893960509 countsByYear W28939605092020 @default.
• W2893960509 countsByYear W28939605092021 @default.
• W2893960509 countsByYear W28939605092022 @default.
• W2893960509 countsByYear W28939605092023 @default.
• W2893960509 crossrefType "journal-article" @default.
• W2893960509 hasAuthorship W2893960509A5006496749 @default.
• W2893960509 hasAuthorship W2893960509A5007665505 @default.
• W2893960509 hasAuthorship W2893960509A5012226414 @default.
• W2893960509 hasAuthorship W2893960509A5019770739 @default.
• W2893960509 hasAuthorship W2893960509A5036764789 @default.
• W2893960509 hasAuthorship W2893960509A5043871151 @default.
• W2893960509 hasAuthorship W2893960509A5047703113 @default.
• W2893960509 hasAuthorship W2893960509A5049192558 @default.
• W2893960509 hasAuthorship W2893960509A5049294543 @default.
• W2893960509 hasAuthorship W2893960509A5054842148 @default.
• W2893960509 hasAuthorship W2893960509A5060572768 @default.
• W2893960509 hasAuthorship W2893960509A5062894702 @default.
• W2893960509 hasAuthorship W2893960509A5066717752 @default.
• W2893960509 hasAuthorship W2893960509A5071440718 @default.
• W2893960509 hasAuthorship W2893960509A5072962574 @default.
• W2893960509 hasAuthorship W2893960509A5073572288 @default.
• W2893960509 hasAuthorship W2893960509A5074173103 @default.
• W2893960509 hasAuthorship W2893960509A5078287634 @default.
• W2893960509 hasAuthorship W2893960509A5078389632 @default.
• W2893960509 hasAuthorship W2893960509A5080125836 @default.
• W2893960509 hasAuthorship W2893960509A5083662358 @default.
• W2893960509 hasBestOaLocation W28939605091 @default.
• W2893960509 hasConcept C121608353 @default.
• W2893960509 hasConcept C126322002 @default.
• W2893960509 hasConcept C141071460 @default.
• W2893960509 hasConcept C142724271 @default.
• W2893960509 hasConcept C143998085 @default.
• W2893960509 hasConcept C204787440 @default.
• W2893960509 hasConcept C207103383 @default.
• W2893960509 hasConcept C27081682 @default.
• W2893960509 hasConcept C2775949291 @default.
• W2893960509 hasConcept C2776256026 @default.
• W2893960509 hasConcept C2776694085 @default.

• next